Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05402332 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801)
A Phase 2 study, sponsored by Eva Morava-Kozicz.
- Not yet
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT05402332: Clinical Trial Phase 2 study, sponsored by Eva Morava-Kozicz.
NCT05402332 is a Phase 2 study that has not yet begun recruiting, run by Eva Morava-Kozicz. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05402332, a Phase 2 study, has not yet begun recruiting, sponsored by Eva Morava-Kozicz.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a clinical trial to evaluate the efficacy of AVTX-801 (D-galactose) on the clinical manifestations of PGM1-CDG in participants currently taking D-galactose.
Primary Outcome
Proportion of participants in each treatment group who experience at least one PGM1-CDG related event (recurrent or prolonged hypoglycemia, elevation of ALT and/or decrease in ATIII) during each treatment period.
Interventions
- DRUG Placebo
- DRUG AVTX-801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2028-03-02 |
| Phase | Phase 2 |
What is known before NCT05402332 opens enrollment
NCT05402332 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05402332 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05402332 about?
NCT05402332 is a clinical study titled "Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801)". This is a clinical trial to evaluate the efficacy of AVTX-801 (D-galactose) on the clinical manifestations of PGM1-CDG in participants currently taking D-galactose.
What is the current status of trial NCT05402332?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2026-10-01. Estimated completion is 2028-03-02.
What interventions are being tested in trial NCT05402332?
The interventions under investigation include: Placebo (DRUG), AVTX-801 (DRUG).
Who is sponsoring clinical trial NCT05402332?
This trial is sponsored by Eva Morava-Kozicz, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05402332's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI